Konakion Paediatric (Phytomenadione)

Konakion Paediatric, a vitamin K preparation, acts on the coagulation cascade to correct deficiencies.

• Vitamin K deficiency bleeding in newborns: prevents hemorrhagic disease by supplying essential cofactor for clotting factor activation.
• Vitamin K deficiency bleeding in infants and children: treats active bleeding episodes and restores normal clotting.
• Anticoagulant reversal: counteracts the effects of vitamin K antagonists such as warfarin in pediatric patients when rapid normalization of coagulation is needed.

• Phytomenadione functions as a cofactor for the γ‑carboxylation of glutamic acid residues on clotting factors II, VII, IX and X in the liver. This enzymatic modification enables the factors to bind calcium, a critical step for their activation in the coagulation cascade, thereby restoring normal clotting ability. The process occurs in the presence of reduced vitamin K, which is regenerated by the enzyme vitamin K epoxide reductase, completing the cycle.

Phytomenadione may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects

• Injection site pain
• Redness or swelling at the administration site
• Mild fever
• Transient flushing

Serious or Rare Side Effects

• Anaphylactic reaction
• Severe hypersensitivity including rash and angioedema
• Hemolysis
• Thrombosis (rare)

When using Konakion Paediatric, several precautions should be observed to ensure safety.

• Assess vitamin K status: verify deficiency before administration.
• Hypersensitivity: avoid in patients with known allergy to phytomenadione or excipients.
• Anticoagulant therapy: monitor coagulation parameters if used alongside warfarin.
• Neonatal use: follow recommended prophylaxis schedule for newborns.
• Concomitant medications: consider potential interactions with drugs affecting vitamin K metabolism.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Phytomenadione can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Warfarin: may diminish anticoagulant effect, requiring dose adjustment.
• Broad‑spectrum antibiotics (e.g., cephalosporins): can reduce intestinal vitamin K synthesis, affecting response.
• Bile acid sequestrants: may decrease absorption of oral phytomenadione.

Moderate Interactions (Monitor Closely)

• Heparin: additive anticoagulant effect may increase bleeding risk.
• Oral contraceptives: may enhance clotting factor activity, requiring monitoring.
• Phenobarbital or other enzyme inducers: may increase metabolism of vitamin K, reducing efficacy.